BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 23851496)

  • 21. The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis.
    Ng TL; Leprivier G; Robertson MD; Chow C; Martin MJ; Laderoute KR; Davicioni E; Triche TJ; Sorensen PH
    Cell Death Differ; 2012 Mar; 19(3):501-10. PubMed ID: 21941369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
    Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM
    PLoS Genet; 2012; 8(8):e1002906. PubMed ID: 22916036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1.
    Zheng M; Wang YH; Wu XN; Wu SQ; Lu BJ; Dong MQ; Zhang H; Sun P; Lin SC; Guan KL; Han J
    Nat Cell Biol; 2011 Mar; 13(3):263-72. PubMed ID: 21336308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells.
    Das F; Dey N; Bera A; Kasinath BS; Ghosh-Choudhury N; Choudhury GG
    J Biol Chem; 2016 Jul; 291(28):14662-76. PubMed ID: 27226530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
    Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
    Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
    Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Strategy for Targeting Aggressive Malignant Gliomas by Disrupting Their Energy Balance.
    Hegazy AM; Yamada D; Kobayashi M; Kohno S; Ueno M; Ali MA; Ohta K; Tadokoro Y; Ino Y; Todo T; Soga T; Takahashi C; Hirao A
    J Biol Chem; 2016 Oct; 291(41):21496-21509. PubMed ID: 27519418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MITF-MIR211 axis is a novel autophagy amplifier system during cellular stress.
    Ozturk DG; Kocak M; Akcay A; Kinoglu K; Kara E; Buyuk Y; Kazan H; Gozuacik D
    Autophagy; 2019 Mar; 15(3):375-390. PubMed ID: 30290719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
    Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
    Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS.
    Zhang J; Kim J; Alexander A; Cai S; Tripathi DN; Dere R; Tee AR; Tait-Mulder J; Di Nardo A; Han JM; Kwiatkowski E; Dunlop EA; Dodd KM; Folkerth RD; Faust PL; Kastan MB; Sahin M; Walker CL
    Nat Cell Biol; 2013 Oct; 15(10):1186-96. PubMed ID: 23955302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.
    Zhang HH; Huang J; Düvel K; Boback B; Wu S; Squillace RM; Wu CL; Manning BD
    PLoS One; 2009 Jul; 4(7):e6189. PubMed ID: 19593385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mTORC2 is required for proliferation and survival of TSC2-null cells.
    Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
    Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.
    Goncharova EA; James ML; Kudryashova TV; Goncharov DA; Krymskaya VP
    PLoS One; 2014; 9(10):e111476. PubMed ID: 25360538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
    Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
    IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
    Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition.
    Sun D; Liu H; Dai X; Zheng X; Yan J; Wei R; Fu X; Huang M; Shen A; Huang X; Ding J; Geng M
    Cancer Lett; 2017 Oct; 406():105-115. PubMed ID: 28687354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer.
    Shao H; Mohamed EM; Xu GG; Waters M; Jing K; Ma Y; Zhang Y; Spiegel S; Idowu MO; Fang X
    Oncotarget; 2016 Jan; 7(4):3832-46. PubMed ID: 26716645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21.
    Cornu M; Oppliger W; Albert V; Robitaille AM; Trapani F; Quagliata L; Fuhrer T; Sauer U; Terracciano L; Hall MN
    Proc Natl Acad Sci U S A; 2014 Aug; 111(32):11592-9. PubMed ID: 25082895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.